Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission

OBJECTIVE: To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. METHOD: Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Juan, Liu, Li, Ma, Runzhi, Pang, Aiming, Yang, Donglin, Chen, Xin, Wei, Jialin, He, Yi, Zhang, Rongli, Zhai, Weihua, Ma, Qiaoling, Jiang, Erlie, Han, Mingzhe, Zhou, Jiaxi, Feng, Sizhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623918/
https://www.ncbi.nlm.nih.gov/pubmed/36316734
http://dx.doi.org/10.1186/s12935-022-02750-4
Descripción
Sumario:OBJECTIVE: To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. METHOD: Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed. RESULTS: Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% ± 4.87% and 83.82% ± 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% ± 7.98% and 15.00% ±7.98%, respectively. CONCLUSION: The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients.

Ejemplares similares